Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (24561)	8/15/1998 9:08:00 PM
From: Machaon	Read Replies (2) \| Respond to of 32384

To All: There is supposed to be a long article on biotechs in the September issue of Money Magazine. I tried to purchase an issue, but the stores only have the August issue. Anyone with a subscription care to comment on the story?

To: Henry Niman who wrote (24561)	8/15/1998 10:09:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

Henry, this was from the August 12th news release about the Seragen merger: <==================================================================> "The Company is working to strengthen its position in CTCL and other non-Hodgkin's lymphoma therapies by filing New Drug Applications for Targretin capsules (bexarotene) and Targretin gel (bexarotene) 1.0% in late 1998 or early 1999." <==================================================================> You have probably already answered this, but, if Ligand files these two NDAs in early 1999, when would you expect FDA action on them? TIA, Bob